PTC Therapeutics (PTCT) CTO exercises options and sells stock under plan
Rhea-AI Filing Summary
PTC Therapeutics, Inc. chief technical operations officer Neil Gregory Almstead reported a series of option exercises and share sales in PTCT common stock. On June 24–25, 2026, he exercised stock options for a total of 26,283 shares at exercise prices including $38.10 and $39.42 per share.
Over the same two days, he sold 26,283 shares of common stock in open-market transactions at prices generally in the mid‑$80s, with individual sale prices such as $87.00 and weighted‑average prices around $85–$86 per share. Following these transactions, Almstead directly holds 60,137 shares of PTCT common stock.
The filing notes that these transactions were carried out under a written Rule 10b5-1 trading plan adopted on November 11, 2025, indicating they were pre‑scheduled rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 1,001 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 19,859 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 100 | $0.00 | -- |
| Exercise | Common Stock | 1,001 | $38.10 | $38K |
| Sale | Common Stock | 582 | $85.24 | $50K |
| Sale | Common Stock | 419 | $86.39 | $36K |
| Exercise | Common Stock | 19,859 | $38.10 | $757K |
| Sale | Common Stock | 8,522 | $85.26 | $727K |
| Sale | Common Stock | 11,337 | $86.51 | $981K |
| Exercise | Common Stock | 100 | $39.42 | $4K |
| Sale | Common Stock | 100 | $87.00 | $9K |
| Exercise | Stock Option (Right to Buy) | 401 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 4,922 | $0.00 | -- |
| Exercise | Common Stock | 401 | $38.10 | $15K |
| Sale | Common Stock | 401 | $85.01 | $34K |
| Exercise | Common Stock | 4,922 | $38.10 | $188K |
| Sale | Common Stock | 4,922 | $85.03 | $419K |
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.84 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.23 to $86.59 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.02 to $86.97 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.